NIH High Priority, Short-Term Project Award (R56)
The High Priority, Short-Term Project Award, R56 grant will fund, for one or two years, high-priority new or competing renewal R01 applications with priority scores or percentiles that fall just outside the funding limits of participating NIH Institutes and Centers (IC). Investigators may not apply for R56 grants. (See June 15, 2004 NIH Guide announcement.)
R56 grants will be awarded beginning in Fiscal Year 2005.
Initial review groups, NIH staff, and the institute and Center Advisory Councils and Boards will review submitted applications in the usual manner. Program administrators may identify creative and innovative approaches within the pool of applications that fall just beyond the established payline. Such applications will be considered for conversion to an R56 award by the IC.
The R56 Award will provide limited, interim research support based on the merit of the pending application. This support is designed to enable the Principal Investigator to gather additional data for revision of the current application. R56 funding will end after one or two years or when the applicant succeeds in obtaining a traditional research project grant.
These one- to two-year awards will underwrite highly meritorious applications and will be funded at levels set by the IC, which can range up to levels recommended by the initial review group and approved by Council.
The R56 award will help early career stage scientists trying to establish research careers as well as experienced scientists who can benefit from interim funding while they revise their applications.
Guidelines for Conversion to an R56
- The R56 grant will be available to domestic R01 applicants only.
- Investigators may not apply for an R56 grant. Competing applications prepared and submitted in accordance with NIH procedures, will be peer reviewed, assigned a priority score and in most cases will receive a percentile rating. The IC will nominate applications for conversion to an R56 from the pool of R01 applications pending award for the current fiscal year. Nominees for the award must be in the most meritorious half of the priority or percentile range. Previously approved, but inactivated, applications from this time period may be considered and, if awarded, will be converted to an R56.
- Note: Investigators do not apply for an R56 grant. Applications for conversion to an R56 will be selected by IC staff from reviewed R01 grants near the payline margins.
- Award amounts can range up to IRG recommend level and will be funded with indirect costs at the negotiated rate.
- R56 awardees are encouraged to submit a revision of their original competing application at the earliest convenient date to be considered for future funding. Applicants are reminded that the limitations on time and the number of amendments described at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-041.html apply to all subsequent revisions.
- If a revised competing application is funded while an R56 award is active, the balance of the R56 Award will be deducted from the total approved amount of the competing award.
- A final progress report, final financial status report, and final invention statement (HHS 568) will be required 90 days after the end of the R56 grant period. The progress report must identify those portions of the original proposal pursued with the R56 Award. If the awardee is successful with a subsequent application, the progress report in the revised application will suffice as a progress report for the R56 Award and a final invention statement will not be required.
Participating NIH Institutes
National Institute of Allergy and Infectious Diseases (NIAID)
Deputy Director, DEA, NIAID, NIH, DHHS
6700-B Rockledge Drive - MSC 7610
Bethesda, MD 20892-7610
For express deliveries, use ZIP code 20817-7610
Phone: (301) 496-7291
FAX: (301) 402-0369
National Cancer Institute (NCI)
Christopher L. Hatch, Ph.D.
Chief, Program Coordination and Referral Branch
Division of Extramural Activities
National Cancer Institute
6116 Executive Blvd., Room 8047
Bethesda, MD 20892-8329
Rockville, MD 20852 (for express/courier delivery)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Kenneth R. Warren, Ph.D.
Director, Office of Scientific Affairs
5635 Fishers Lane
Bethesda, MD 20892-1705
National Center on Complementary and Alternative Medicine (NCCAM)
Richard L. Nahin, Ph.D., MPH
Senior Advisor for Scientific Coordination and Outreach
National Center for Complementary and Alternative Medicine
9000 Rockville Pike
Bldg. 31, Rm. 2B11
Bethesda, MD 20892-2182
National Institute on Aging (NIA)
Dr. Miriam F. Kelty, Ph.D
Associate Director, Extramural Activities
7201 Wisconsin Ave, Room 2C218, MSC 2292
Bethesda, MD 20892
National Institute of Environmental Health Sciences (NIEHS)
Anne P. Sassaman
Director, Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institutes of Health
P.O. Box 12233
Research Triangle Park, NC. 27709
Phone: (919) 541-7723
Fax: (919) 541-2843
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Joyce A. Hunter, Ph.D.
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Two Democracy Plaza, Room 714
6707 Democracy Boulevard
Bethesda, MD 20892-5456
Phone: (301) 594-0056
Fax: (301) 480-4125
National Institute on Drug Abuse (NIDA)
Teresa Levitin, Ph.D.
Director, Office of Extramural Affairs
6101 Executive Blvd, Room 220 MSC 8401
Bethesda, MD 20892-8401
Phone: 301 443-2755
Fax: 303 443-0538
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Cheryl A. Kitt, Ph.D.
Director, Extramural Program
National Institute of Arthritis and Musculoskeletal and Skin Diseases
One Democracy Plaza
6701 Democracy Blvd., Room 804
Bethesda, MD 20892-4872
National Library of Medicine (NLM)
Valerie Florance, Ph.D.
Deputy Director, Division of Extramural Programs
Rockledge 1, Suite 301,
6705 Rockledge Drive
Bethesda, MD 20892
Phone: (301) 594-4882
Fax (301) 402-2952